Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.54 |
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318085 | 0.89 | SIGMAR1 (0.49) | SIGMAR1TMEM97CCR3PRMT6CARM1 | |
| SCHEMBL3317496 | 0.85 | CCR3 (0.53) | SIGMAR1TMEM97CCR3PRMT6CARM1 | |
| SCHEMBL3316578 | 0.84 | DRD2 (0.50) | SIGMAR1PRMT6CARM1HRH3 | |
| SCHEMBL3316138 | 0.75 | LTA4H (0.47) | SIGMAR1HRH3 | |
| SCHEMBL3318052 | 0.75 | LTA4H (0.47) | SIGMAR1HRH3 | |
| SCHEMBL3316879 | 0.75 | LTA4H (0.47) | SIGMAR1HRH3 | |
| SCHEMBL3993586 | 0.74 | CXCR3 (0.45) | HRH3 | |
| SCHEMBL3316782 | 0.74 | LTA4H (0.48) | HRH3 | |
| SCHEMBL3313308 | 0.73 | HTR7 (0.49) | SIGMAR1PRMT6CARM1KCNH2 | |
| SCHEMBL467346 | 0.72 | HRH3 (0.46) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066648-B1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2017-04-12 | — | — | EP | claimed |
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | claimed |
| EP-2066648-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-06-10 | — | — | EP | claimed |
| WO-2008015266-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-07 | — | — | WO | claimed |
| EP-2066648-B1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2017-04-12 | — | — | EP | disclosed |
| EP-2066648-B1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2017-04-12 | — | — | EP | disclosed |
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2066648-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008015266-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015266-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885TMEM97 2/4885CCR3 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.